Research
Hormonal
Exposure to specific endocrine-disrupting chemicals (e.g., phthalates, BPA, vinclozolin) is associated with an increased risk of Testicular Dysgenesis Syndrome (TDS) and reduced male fertility.
For men concerned about fertility, minimizing exposure to known endocrine disruptors like phthalates and BPA (found in some plastics and receipts) is advisable, especially if planning a family. This is particularly relevant for those with a history of reproductive issues, as early developmental exposure may have lasting effects.
ModerateSupportsMEDIUM confidence
EDCs seems to have a causative role in the onset of testicular dysgenesis syndrome (TDS)... Phthalates, vinclozolin, acetaminophen, and polybrominated diphenyl ethers (PBDE) seem to play a significant etiopathogenetic role in the onset of TDS.
Why this rating
Review paper citing multiple studies, but acknowledges complexity and lack of standardization in human studies.
Source
Endocrine Disrupting Chemicals: Effects on Endocrine Glands
Rosa Lauretta et al. · Frontiers in Endocrinology · 2019
DOI 10.3389/fendo.2019.00178
narrative_reviewCited 332×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Occupational exposure to pesticides and biocides is associated with an increased risk of thyroid cancer, particularly in male adults.Good
- Exposure to endocrine-disrupting chemicals (EDCs) during early development can alter adipose tissue homeostasis and energy regulation, predisposing individuals to obesity and metabolic syndrome even with low-calorie diets and increased physical activity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →